Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
(NasdaqGM:ETON), Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 million Launched KHINDIVI(TM) (hydrocortisone) Oral Solution Reached 100 active INCRELEX(R) […]